• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    PMGC Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    7/7/26 5:18:15 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ELAB alert in real time by email
    false 0001840563 0001840563 2026-06-30 2026-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d) OF

    THE SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): June 30, 2026

     

    PMGC Holdings Inc.
    (Exact name of registrant as specified in its charter)

     

    Nevada   001-41875   33-2382547
    (State or other jurisdiction
    of incorporation)
      (Commission File Number)   (I.R.S. Employer
    Identification No.)

     

    c/o 120 Newport Center Drive
    Newport Beach, CA
      92660
    (Address of principal executive offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: (888) 445-4886

     

    N/A

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, $0.0001 par value   ELAB   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 1.01 Entry into a Material Definitive Agreement.

     

    Standard Exclusive License Agreement between NorthStrive Defense Tech LLC and Licensor

     

    As of June 30, 2026 (the “Effective Date”), NorthStrive Defense Tech LLC (“NorthStrive Defense Tech”), a wholly owned subsidiary of PMGC Holdings Inc. (the “Company”), entered into a Standard Exclusive License Agreement with Know-How (the “License Agreement”) with a certain licensor (“Licensor”). Under the License Agreement, Licensor granted NorthStrive Defense Tech a worldwide, non-transferable, exclusive license (“License”) to make, have made, use, sell, have sold, and import licensed products covered by U.S. Patent No. 12,291,334 and associated know-how in the field of aerospace and defense technologies (such fields, the “Licensed Field”). NorthStrive Defense Tech has the right to grant sublicenses to third parties, subject to the terms of the License Agreement.

     

    NorthStrive Defense Tech has provided Licensor with a development plan, pursuant to which NorthStrive Defense Tech intends to develop and commercialize Licensed Products (as defined below). On or before January 15 of each calendar year, NorthStrive Defense Tech shall provide Licensor with a written development report that describes in detail as of that reporting period, all development and commercialization activities for each Licensed Product and, at least one year before commencement of commercial production of Licensed Products, specifics of planned manufacturing or production, together with an updated Development Plan for the next annual period. NorthStrive Defense Tech’s failure to perform substantially in accordance with the then-current development plan or meet any diligence milestone constitutes, in each case, shall be a material breach of the License Agreement.

     

    In partial satisfaction of its obligations to bring Licensed Products to market, NorthStrive Defense Tech agreed to achieve the diligence milestones set forth in the License Agreement within the time specified for each milestone. NorthStrive Defense Tech may request an extension of any milestone due date, which request Licensor shall consider in good faith, provided that NorthStrive Defense Tech has evidenced commercially reasonable efforts to achieve the milestone by the date due. The milestones in the License Agreement are good-faith projections and are subject to change The parties may adjust timelines by mutual written agreement. Failure to meet a milestone date shall not constitute a breach of the License Agreement provided that NorthStrive Defense Tech has timely requested an extension under Section 3.3(b) of the License Agreement.

     

    In consideration of the License, NorthStrive Defense Tech shall pay to Licensor a non-refundable, non-creditable license issue fee of within thirty (30) days of the Effective Date. NorthStrive Defense Tech shall also pay to Licensor a non-refundable, non-creditable annual license maintenance fee upon each anniversary of the Effective Date, commencing on the first anniversary and ending in the year the first Net Sales (as defined in the License Agreement) of a Licensed Product is achieved.

     

    NorthStrive Defense Tech also agreed to pay royalties to Licensor according to the payment terms set forth in the License Agreement. NorthStrive Defense Tech shall also make certain sublicense payments to Licensor, as further set forth in the License Agreement.

     

    1

     

     

    The term of the License Agreement begins on the Effective Date and, unless earlier terminated in accordance with Section 8 of the License Agreement, continues until the date of the last to expire Royalty Term (as defined below, and such term, “Term”). NorthStrive Defense Tech’s obligation to pay royalties under the License Agreement will continue on a Licensed Product-by-Licensed Product and country-by-country basis until the later of: (a) the last to expire of the Patent Rights (as defined in the License Agreement) covering the Licensed Product in that country; or (b) twelve (12) years from the date of first Net Sale (as defined in the License Agreement) for the Licensed Product in that country (“Royalty Term”). NorthStrive Defense Tech may terminate the License Agreement in whole or, with Licensor’s consent, with respect to a subset of the rights licensed thereunder, without cause at any time after the first anniversary of the Effective Date by giving at least sixty (60) days’ prior written notice to Licensor, and stating the reasons for termination in the notice. Licensor may terminate the License Agreement immediately upon notice to NorthStrive Defense Tech if Licensor does not receive the license issue fee and patent expense reimbursement pursuant to the License Agreement and, if applicable, certificates representing the Equity Interests (as defined in the License Agreement) to be issued to LicensorR pursuant to the License Agreement, within thirty (30) days of the Effective Date. Licensor may terminate the License Agreement upon written notice if the NorthStrive Defense Tech commits a breach and fails to remedy such breach within thirty (30) days after receiving written notice thereof. Licensor may terminate the License Agreement immediately upon notice to NorthStrive Defense Tech upon the occurrence of the second separate default by NorthStrive Defense Tech within any consecutive three-year period for failure to pay any monies due under the License Agreement when due. The License Agreement shall immediately terminate, unless prohibited by applicable law, if the other party enters liquidation, has a receiver or administrator appointed over any assets related to the License Agreement, makes any voluntary arrangement with any of its creditors, or ceases to carry on business, or any similar event under the law of any foreign jurisdiction.

     

    “Know-How” means information and materials existing as of the Effective Date, owned by Licensor, related to the subject matter of the Patent Rights, generated by the Investigator (as defined in the License Agreement) or those working under the Investigator’s direction, and selected by Licensor, including the processes, techniques, data, and materials identified on Appendix A of the License Agreement. If Know-How is provided in the form of: (a) tangible materials, then all progeny and modified and unmodified derivatives of the materials made by or on behalf of NorthStrive Defense Tech or a sublicensee are included within this definition of Know-How; and/or (b) software or other copyrightable work, then all derivative works made by or on behalf of NorthStrive Defense Tech or any sublicensee are included within this definition of Know-How.

     

    “Licensed Products” means any product or process that: (a) is covered in whole or in part by a Valid Claim (as defined in the License Agreement) within the Patent Rights (as defined in the License Agreement); (b) is manufactured by using a process that is covered in whole or in part by a Valid Claim within the Patent Rights and/or (c) that is Know-How or the development, manufacture, use, sale or importation of which incorporates, uses, has used or is derived from Know-How.

     

    The foregoing description of the License Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the License Agreement, a copy of which is attached hereto as Exhibit 10.1 and is incorporated herein by reference.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit No.   Description
    10.1+   Standard Exclusive License Agreement with Know-How between NorthStrive Defense Tech LLC and Licensor.
    104   Cover Page Interactive Data File (formatted in Inline XBRL).

     

    + Portions of this exhibit have been redacted.

     

    2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: July 7, 2026

     

    PMGC Holdings, Inc.  
         
    By: /s/ Graydon Bensler  
    Name:   Graydon Bensler  
    Title: Chief Executive Officer  

     

    3

     

     

    Get the next $ELAB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ELAB

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ELAB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NorthStrive Defense Tech Executes Definitive Exclusive License Agreement with Florida State University Research Foundation for Multi-Domain Drone Payload Technology Across Defense, Aerospace and Maritime Applications

    Definitive license agreement formalizes exclusive, worldwide, sublicensable rights to patented multi-domain drone payload technology for aerospace and defense applicationsAgreement follows the binding term sheet and sponsored research agreement announced earlier this yearLicense covers U.S. Patent No. 12,291,334 and related know-how, with a multi-year development plan targeting prototype completion, non-dilutive funding applications, and first commercial sale NEWPORT BEACH, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- NorthStrive Defense Tech LLC ("NorthStrive Defense Tech"), a wholly owned subsidiary of PMGC Holdings Inc. (the "Company") (NASDAQ:ELAB) formed to license and commercialize def

    7/13/26 7:30:00 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NorthStrive Biosciences to Advance EL-22 Manufacturing Characterization with Quantitative FACS Analysis of Latent Myostatin Antigen Expression

    Independent flow cytometry (FACS) study will quantify latent myostatin antigen expression on NorthStrive-manufactured Lactobacillus casei and establish comparability against EL-22 material previously manufactured by MOA Life Plus Co. Ltd. Work is intended to strengthen EL-22 product identity and manufacturing consistency as NorthStrive advances a differentiated engineered probiotic designed to help preserve muscle during weight loss, including with GLP-1 receptor agonists NEWPORT BEACH, Calif., July 10, 2026 (GLOBE NEWSWIRE) -- NorthStrive Biosciences Inc. ("NorthStrive Biosciences"), a subsidiary of PMGC Holdings Inc. (NASDAQ:ELAB) ("PMGC" or the "Company"), today announced plans to ini

    7/10/26 7:30:00 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PMGC Holdings Inc. Announces Merger of AGA Precision Systems into A&B Aerospace

    Strategic consolidation of two precision manufacturing portfolio companies expected to streamline operations, shared resources, and strengthen the companies’ aerospace manufacturing platform NEWPORT BEACH, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:ELAB) ("PMGC" or the "Company") today announced that it has merged AGA Precision Systems LLC ("AGA") into A&B Aerospace, Inc. ("A&B Aerospace"), with A&B Aerospace expected to be the surviving operating entity. The merger is designed to simplify PMGC’s aerospace precision manufacturing platform by consolidating two related businesses under one corporate structure. Following the merger, AGA will cease to exist as a sep

    7/6/26 7:30:00 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Executive Officer Bensler Graydon

    4 - PMGC Holdings Inc. (0001840563) (Issuer)

    6/3/26 4:01:11 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Parry Jeffrey

    4 - PMGC Holdings Inc. (0001840563) (Issuer)

    6/3/26 8:09:25 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Kovalyov George

    4 - PMGC Holdings Inc. (0001840563) (Issuer)

    6/2/26 8:10:59 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAB
    SEC Filings

    View All

    PMGC Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - PMGC Holdings Inc. (0001840563) (Filer)

    7/9/26 4:01:54 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PMGC Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - PMGC Holdings Inc. (0001840563) (Filer)

    7/7/26 5:18:15 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PMGC Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - PMGC Holdings Inc. (0001840563) (Filer)

    7/1/26 7:31:32 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Elevai Labs Inc.

    SC 13G - Elevai Labs Inc. (0001840563) (Subject)

    11/14/24 5:53:26 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Elevai Labs Inc.

    SC 13G - Elevai Labs Inc. (0001840563) (Subject)

    10/2/24 4:01:03 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Elevai Labs Inc.

    SC 13G - Elevai Labs Inc. (0001840563) (Subject)

    10/1/24 4:01:02 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAB
    Financials

    Live finance-specific insights

    View All

    PMGC Holdings (NASDAQ: ELAB) Acquires A&B Aerospace, Inc.

    Precision machining and aerospace, defense manufacturing company contracted by long standing Tier 1 customers that include Boeing, Honeywell International Inc., and Moog Inc.*AS9100D and ISO 9001:2015 certified NEWPORT BEACH, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:ELAB) ("PMGC" or the "Company"), a diversified holding company currently executing a targeted roll-up strategy in U.S.-based precision manufacturing companies, has acquired A&B Aerospace, Inc. ("A&B Aerospace" or "A&B"), Founded in 1948, A&B Aerospace is a precision machining and aerospace manufacturing company specializing in high-tolerance parts and assemblies for the aerospace industry. Headquart

    5/13/26 4:03:00 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NorthStrive Defense Tech Acquires Multi-Domain Drone Payload Technology Option for Defense and Commercial Applications

    NEWPORT BEACH, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- NorthStrive Defense Tech LLC ("NorthStrive Defense Tech"), a wholly-owned subsidiary of PMGC Holdings Inc. (the "Company") (NASDAQ:ELAB), today announced it has acquired rights to a novel drone technology through an exclusive option agreement ("Option Agreement") with a corporation. The Option Agreement provides NorthStrive Defense Tech with an exclusive option, within the aerospace and defense technologies field ("Field"), to get an exclusive license as to certain patent rights for U.S. Patent No. 12,291,334, covering a next-generation drone system designed to transport payloads across air and water environments. The option ("Opti

    4/6/26 7:30:00 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PMGC Holdings Inc. Announces the Acquisition of SVM Machining, Inc.

    NEWPORT BEACH, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:ELAB) ("PMGC" or the "Company"), a diversified public holding company announced that it has completed the acquisition of SVM Machining, Inc. ("SVM"). Founded in 1997 by Mark Serpa, SVM (aka Silicon Valley Manufacturing) is a Northern California-based ISO 9001:2015 Certified CNC precision machining and manufacturing services company serving medical, aerospace, biotech & pharmaceutical, semiconductor, and transportation markets. This transaction represents PMGC's third California based CNC machine shop acquisition to date, expanding PMGC's growing footprint in precision manufacturing and furthering its stra

    2/3/26 7:30:00 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAB
    Leadership Updates

    Live Leadership Updates

    View All

    PMGC Holdings Inc. Expands Investment & M&A Efforts, Actively Seeking Acquisitions and Investments Through Strategic Sponsorship of TCA Venture Group

    NEWPORT BEACH, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (the "Company" or "PMGC," "our," or "we") (NASDAQ:ELAB), a diversified holding company, is proud to announce its annual sponsorship of TCA Venture Group's ("TCA") Orange County network for 2025. As a Southern California Network Sponsor, PMGC is actively pursuing investments and M&A opportunities to strengthen its portfolio while fostering local business growth and expanding its market presence. TCA Venture Group (formerly known as Tech Coast Angels) is one of the largest and most active angel investor networks in the United States. With a history spanning over 25 years, TCA has been instrumental in funding early-s

    2/27/25 8:00:00 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elevai Labs Inc. Subsidiary, Elevai Biosciences, Continues to Advance its Scientific Advisory Board with the Appointment of Orian Shirihai, MD, PhD

    Professor of Medicine at the University of California, Los Angeles (UCLA), where he serves as Director of the UCLA Metabolism Research Theme.Over 180 publications in the field of obesity & metabolism, along with multiple NIH-funded projects as Principal Investigator.Dr. Shirihai is a renowned researcher regularly invited as a keynote speaker at annual scientific conferences and has consulted for Johnson & Johnson, Bayer, AstraZeneca and Pfizer, among other healthcare companies. NEWPORT BEACH, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ:ELAB) ("Elevai" or the "Company"), a pioneering force in medical aesthetics, announced the appointment of Orian Shirihai, MD, PhD, t

    7/30/24 9:00:26 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elevai Labs Forms New Scientific Advisory Board for its Weight Loss Programs

    NEWPORT BEACH, Calif., June 14, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ:ELAB) ("Elevai" or the "Company"), a pioneering force in medical aesthetics, announced the formation of a new Scientific Advisory Board to support the advancement of EL-22, a first-in-class engineered probiotic approach, to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. "We are honored to be forming a Scientific Advisory Board with renowned members that possess deep and complementary knowledge in metabolic diseases, obesity, weight management, muscle preservation and physical function in addition to significant experience in clinical

    6/14/24 9:00:00 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care